1. Introduction {#sec1}
===============

Free-living amoebae (FLA) are ubiquitous and opportunistic protozoa widely distributed in nature. They can be found in natural and artificial environments such as soil, dust, rivers, or swimming pools, cooling towers of nuclear power plants or drinking water distribution networks ([@bib42], [@bib28], [@bib44]). These amoebae present two main forms in their life cycle: the vegetative and motile form, called trophozoite, and the latent and non-motile form, called cyst, the latter being responsible of FLA dissemination in nature due to its capacity to resist to hostile environmental conditions. Remarkably, cysts of *Acanthamoeba* sp. have been described to resist to disinfection treatments such as chlorine, radiations, or hydrogen peroxide ([@bib1], [@bib51]). Besides their ability to host diverse pathogenic microorganisms such as viruses, bacteria or fungi and to protect them from environmental conditions ([@bib16]), some FLA, such as *Acanthamoeba* sp., *Naegleria fowleri* or *Balamuthia mandrillaris*, are opportunistic pathogens and can cause severe ocular or cerebral pathologies ([@bib54]). For example, FLA from the genus *Acanthamoeba* can either cause *Acanthamoeba* Keratitis (AK), a painful and sight-threatening corneal infection which can lead to blindness without treatment, or Granulomatous Amoebic Encephalitis (GAE), a severe cerebral infection affecting mostly immunocompromised patients ([@bib44], [@bib46]).

Currently, the treatment of AK involves membrane-acting agents, such as chlorhexidine or polyhexamethylene biguanide, in combination with a diamidine (propamidine or hexamidine) for a period of up to one year, with infection recurrence in 10% of cases ([@bib46], [@bib5]). However, GAE remains lethal in more than 90% of cases, even after treatment with various combinations of drugs involving amphotericin B, rifampicin, cotrimoxazole, miltefosine, pentamidine, flucytosine, pyrimethamine and cotrimoxazole combination but also sterol targeting agents such as ketoconazole, voriconazole or clotrimazole ([@bib44], [@bib46], [@bib36]). Among these drugs, amphotericin B is one of the most commonly used for the treatment of GAE infections ([@bib46], [@bib36]). This antifungal drug has been described to bind preferentially to ergosterol, one of the major sterols in the plasma membrane of *Acanthamoeba* sp., leading to pore formation, ion leakage and cell death ([@bib48], [@bib57]). Besides this homeostatic effect, amphotericin B has also been shown to induce an apoptosis-like mechanism in fungal cells as well as in parasites from the genus *Leishmania* sp., involving a loss of mitochondrial membrane potential and a rise of reactive oxygen species (ROS) ([@bib25], [@bib32], [@bib7]). In *Acanthamoeba castellanii*, the disruption of mitochondrial energetics and membrane potential has also been associated with oxidative stress ([@bib53]). However, the mode of action of amphotericin B in *Acanthamoeba* sp. remains currently not elucidated. In a first part of this study, the activity of antimicrobial drugs used in the treatment of AK, GAE or other parasitic diseases were evaluated *in vitro* against the FLA *Acanthamoaeba castellanii* at different times of incubation. Among them, amphotericin B was the only one showing a drastic change of activity as a function of time. The susceptibility of *Acanthamoeba* sp. for this polyene drug was further investigated in the present study.

2. Materials and methods {#sec2}
========================

2.1. Chemicals {#sec2.1}
--------------

All chemicals, including amphotericin B (Fungizone^®^), were purchased from Sigma-Aldrich (Saint-Quentin-Fallavier, France), except for miltefosine, uranyle acetate and epoxy resin (Low Viscosity Premix Kit Medium) which were provided by Zentaris laboratories (Frankfurt, Germany), Merck (Fontenay-sous-Bois, France) and Agar Scientific (Oxford instruments, Gometz-la-Ville, France), respectively.

2.2. Acanthamoeba *cultures* {#sec2.2}
----------------------------

Two *Acanthamoeba castellanii* strains (ATCC 30010 strain and CCAP 1534/3 strain) isolated from environment, and two *Acanthamoeba polyphaga* strains (ATCC 50371 strain and CCAP 1501/3G strain) isolated from human eye infection were maintained twice a week at 27 °C in the dark without shaking in PYG medium (ATCC medium 712) containing 2% (w/v) proteose peptone, 0.1% (w/v) yeast extract, 400 μM CaCl~2~, 4 mM MgSO~4~, 2.5 mM Na~2~HPO~4~, 2.5 mM KH~2~PO~4~, 50 μM (NH~4~)~2~Fe(SO~4~)~2~, 100 mM glucose.

2.3. In vitro *evaluation of anti-acanthamoebal activities* {#sec2.3}
-----------------------------------------------------------

All compounds were evaluated on *A. castellanii* and *A. polyphaga* using a resazurin assay adapted from [@bib30]. Briefly, two-fold serial dilutions of the different compounds were performed from a maximal concentration of 100 μM--0.05 μM in 100 μl PYG medium in a 96-well plate (TPP, Dutscher, Brumath, France). *Acanthamoeba* strains were then added to each well at 5 × 10^4^ amoebae/mL and the plates were further incubated at 27 °C for 3, 4 and 5 days in the dark without shaking. 20 μL of a resazurin solution at 1 mM were then added to each well, and the plates were incubated 8 h at 27 °C. The conversion of resazurin into resorufin was monitored by measuring OD~570nm~ (resorufin) and OD~600nm~ (resazurin; Labsystems Multiskan MS). The anti*-*acanthamoebal activity was expressed as IC~50~ (concentration of drug inhibiting 50% of amoebae growth in comparison to the control culture). The results were presented as the mean ± SD of independent experiments (n = 6).

The evaluation of drug interactions through their combination was performed as follows. From the determination of the IC~50~ of two compounds (A and B) at 3 days of treatment, the Fractional Inhibitory Concentration Index (FICI) was determined after the same period of treatment, according to the protocol previously described ([@bib34]), to characterize the type of drugs interaction, namely antagonism, additivity or synergism. Briefly, the top concentration was firstly calculated for compound A and compound B as follows:$$\left\lbrack {{Compound}\ A} \right\rbrack_{top}{=4I}C_{50}^{{Compound}\ A}\quad{and}\quad\left\lbrack {{Compound}\ B} \right\rbrack_{top}{=4I}C_{50}^{{Compound}\ B}$$

Compounds A and B were then mixed at different ratios of concentrations as follows:-Association 1 was composed of 80% \[Compound A\]~top~ and 20% \[Compound B\]~top~-Association 2 was composed of 60% \[Compound A\]~top~ and 40% \[Compound B\]~top~-Association 3 was composed of 40% \[Compound A\]~top~ and 60% \[Compound B\]~top~-Association 4 was composed of 20% \[Compound A\]~top~ and 80% \[Compound B\]~top~

Fractional Inhibitory Concentrations (FICs) were then calculated for each of the four drug associations according to the following equations:$${FI}C_{1}^{A}=\frac{IC_{50}^{A{({{Assoc}\ 1})}}}{IC_{50}^{A}}\quad{and}\quad{FI}C_{1}^{B}=\frac{IC_{50}^{B{({{Assoc}\ 1})}}}{IC_{50}^{B}}$$

Then, $\sum{FIC}$ was calculated for each association according to the following equation:$${\sum{FIC}}_{1} = {FI}C_{1}^{A} + {FI}C_{1}^{B}$$

The Fractional Inhibitory Concentrations Index (FICI) was then determined as the mean of the ΣFIC for the four drug associations as follows:$${FICI=}\frac{{\sum{FIC}}_{1} + {\sum{FIC}}_{2} + {\sum{FIC}}_{3} + {\sum{FIC}}_{4}}{4}$$

Accordingly, drug combinations displayed a synergistic, additive or antagonist effect if FICI ≤ 0.5, 0.5 \< FICI ≤ 4, or FICI \>4, respectively ([@bib34]). The results were presented as the mean ± SD of independent experiments (n = 4).

In order to analyze the effect of amphotericin B pre-incubation in the culture medium on the evolution of the polyene drug activity, 250 μM amphotericin B was incubated in PYG for 7 days in the dark at 27 °C, prior to add amoebae at 5 × 10^4^ amoebae/mL and to determine the IC~50~ of amphotericin B at 3, 4 and 5 days of treatment, as described above. The results were presented as the mean ± SD of independent experiments (n = 3).

To study the effect of *Acanthamoeba* pre-incubation with amphotericin B on the evolution of the polyene drug activity, *A. castellanii* (ATCC 30010 strain) were cultured in the presence of increasing concentrations of amphotericin B until reaching a maximum of 250 μM, and were further maintained weekly at this concentration for 3 months before analyzing their growth and their susceptibility for the drug. The excess of amphotericin B was removed by washing amoebae 3 times in PYG medium without amphotericin B prior to determine the anti-acanthamoebal activity of the drug at 3, 4 and 5 days of treatment, as described above. The results were presented as the mean ± SD of independent experiments (n = 3).

Growth curves were generated by counting amoebae under light microscope using a Malassez chamber at regular intervals of time, as mentioned in the text, for a period of ten days. The results were presented as the mean ± SD of independent experiments (n = 3). The amoebae cultured in the presence of 250 μM amphotericin B for 3 months were named "AmB" in this work.

2.4. Analysis of Acanthamoeba mechanism of resilience for amphotericin B {#sec2.4}
------------------------------------------------------------------------

*Acanthamoeba* cultures (ATCC 30010 strain) in log phase were firstly incubated at 1 × 10^5^ amoebae/mL for 4 h at 27 °C in 15 mL of PYG medium containing KCN, glibenclamide, valinomycin, calcimycin, BAPTA-AM, valspodar, latrunculin B, vinblastine, wortmannin or dichlorobenzonitrile at twice the concentrations described in [Table S1](#appsec1){ref-type="sec"}. These concentrations were determined to inhibit ≤25% of amoebal growth after 3 days of treatment at 27 °C ([Table S1](#appsec1){ref-type="sec"}). Two fold dilutions of amphotericin B were then performed from a maximal concentration of 500 μM in 100 μl PYG medium in a 96-well plate and 100 μL of *Acanthamoeba* subcultures containing the drugs, to avoid any potential reversibility of action, was added to each well containing amphotericin B. The anti-acanthamoebal activity was further determined at 3, 4 and 5 days of treatment, as described above. The results are presented as the mean ± SD of independent experiments (n = 3).

2.5. Transmission electron microscopy {#sec2.5}
-------------------------------------

*Acanthamoeba castellanii* (ATCC 30010 strain) in log phase were treated with 250 μM amphotericin B for 3, 7 or 10 days, before centrifugation at 3000 g for 30 min at room temperature. Cell pellets were then fixed for 2 h at room temperature by replacing the supernatant by a fixative buffer containing 3% (v/v) glutaraldehyde, 1% (v/v) para-formaldehyde, 0.1 M sodium cacodylate pH 7.5. Cells were washed with 0.1 M sodium cacodylate buffer pH 7.5, incubated for 1 h in 1% osmium tetroxide in 0.1 M sodium cacodylate pH 7.5 and then rinsed 3 times in 0.1 M sodium cacodylate pH 7.5. Pellets were further centrifuged in 2% low melting point agarose to obtain concentrated pellets in 1 mm^3^ cubes. Dehydration in graded acetone series (50-70-90-100%) and embedding in graded series (50-100-100%) of epoxy resin (Low Viscosity Premix Kit Medium) mixed with acetone were processed manually. Blocks were then polymerized for 20 h at 60 °C and ultrathin sections (90 nm) were cut with an ultramicrotome UC6 (Leica Microsystems, Germany) and collected on formvar carbon-coated copper grids. Ultrathin sections were stained with uranyl acetate 2%, washed 3 times with water and treated by Reynolds lead citrate in order to increase membrane contrast ([@bib41]). Grids were washed 3 times for 5 min with water before observation with a JEOL JEM-1400 transmission electron microscope operating at 80 kV. Images were acquired using a postcolumn high-resolution (11 megapixels) high-speed camera (SC1000 Orius; Gatan, France) with Digital Micrograph software (Gatan, v2.32.888.0), and further processed using ImageJ software (v. 1.47).

3. Results {#sec3}
==========

In a first part of this work, 15 compounds previously used for the treatment of AK, GAE, or other parasitic diseases, were evaluated for their *in vitro* activity on *A. castellanii* ([Table 1](#tbl1){ref-type="table"}). Among them, the most active compound after 3 days of treatment was hexamidine with an IC~50~ at 0.04 μM. With the same treatment duration, voriconazole and clotrimazole displayed also promising activities with IC~50~ of 0.32 μM and 0.77 μM, respectively, and interesting activities with IC~50~ at the micromolar range or under 10 μM were obtained with chlorhexidine, pentamidine, flucytosine, amphotericin B, propamidine, miltefosine and ketoconazole. All the other molecules analyzed displayed an IC~50~ value superior to 10 μM. Indeed, paromomycin, a drug commonly used in the treatment of leishmaniasis ([@bib52]), but also in the treatment of intestinal amoebiasis ([@bib24]), showed a modest IC~50~ value of 16.28 μM.Table 1*In vitro* activities of antimicrobial drugs on *Acanthamoeba castellanii*.Table 1DrugIC~50~ (μM) ± SD at 3 daysIC~50~ (μM) ± SD at 4 daysIC~50~ (μM) ± SD at 5 daysHexamidine0.04 ± 0.020.04 ± 0.010.06 ± 0.01Voriconazole0.32 ± 0.210.40 ± 0.140.52 ± 0.23Clotrimazole0.77 ± 0.040.74 ± 0.550.86 ± 0.40Chlorhexidine1.03 ± 0.141.10 ± 0.011.26 ± 0.38Pentamidine1.11 ± 0.101.05 ± 0.111.11 ± 0.01Flucytosine4.65 ± 0.137.65 ± 0.655.99 ± 0.78**Amphotericin B6.78** ± **1.2465.98** ± **5.91120.63** ± **8.76**Propamidine7.59 ± 3.258.96 ± 1.4514.24 ± 3.38Miltefosine7.70 ± 2.6411.22 ± 2.6513.85 ± 5.59Ketoconazole7.98 ± 2.557.91 ± 3.7811.58 ± 8.15Paromomycin^∗^16.28 ± 3.0918.84 ± 3.5119.89 ± 1.60Pyrimethamine^∗^49.60 ± 4.1647.74 ± 3.9261.02 ± 7.90Rifampicin\>100NDNDMetronidazole^∗^\>100NDNDCotrimoxazole\>100NDND[^1][^2]

The three most active compounds, namely hexamidine, voriconazole, and clotrimazole, were then evaluated on *A. castellanii* in association with most of the drugs presenting an IC~50~ under 10 μM in order to determine the interaction effect of drug combinations, hoping for a synergistic effect ([Table 2](#tbl2){ref-type="table"}). Apart from the FICI obtained with the association hexamidine-chlorhexidine which was at 4.84 corresponding to an antagonistic effect, all the FICI were between 0.5 and 4 reflecting only an additive effect, and thus, an absence of any synergistic effect with the drug combinations analyzed ([@bib34]).Table 2Activities of drug combinations on *Acanthamoeba castellanii*.Table 2CombinationsFICI[a](#tbl2fna){ref-type="table-fn"}Hexamidine - Voriconazole1.18Hexamidine - Clotrimazole1.04Hexamidine - Chlorhexidine4.84Hexamidine - Pentamidine1.29Hexamidine - Amphotericin B0.80Hexamidine - Miltefosine1.33Voriconazole - Clotrimazole1.47Voriconazole - Chlorhexidine1.23Voriconazole - Pentamidine1.34Voriconazole - Amphotericin B1.12Voriconazole - Miltefosine1.41Clotrimazole - Chlorhexidine1.29Clotrimazole - Pentamidine1.21Clotrimazole - Amphotericin B1.10Clotrimazole - Miltefosine1.47[^3][^4]

In addition, the activity of all the 15 compounds was also evaluated after 4 and 5 days of treatment. Interestingly, the activities of all compounds were stable with time, suggesting a sufficient time for drug effect, except for amphotericin B which displayed a marked increase of IC~50~ values between 3 and 5 days of treatment ([Table 1](#tbl1){ref-type="table"}). Furthermore, a similar evolution of amphotericin B IC~50~ with time was observed in one other *A. castellanii* strain (CCAP 1534/3) as well as with two strains of *A. polyphaga* (ATCC 50371 and CCAP 1501/3G; [Table 3](#tbl3){ref-type="table"}). In order to analyze the stability of drug activity, amphotericin B was incubated in culture medium for 7 days before evaluating the IC~50~ on *A. castellanii* at 3, 4 and 5 days. As shown in [Table 4](#tbl4){ref-type="table"}, the activity of pre-incubated amphotericin B was similar to the control at each incubation time. These results show that amphotericin B activity remained stable independently of a pre-incubation in culture medium. An attempt to select an amphotericin B-resistant strain was also performed by culturing *A. castellanii* with increasing concentrations of amphotericin B to a maximum of 250 μM. These amoebae were then maintained 3 months at this drug concentration before starting *in vitro* evaluations. Surprisingly, the susceptibility of these "AmB" amoebae to amphotericin B, either at 3, 4 or 5 days of treatment, was comparable to a naive control strain, indicating that the AmB strain was actually not resistant to amphotericin B ([Table 5](#tbl5){ref-type="table"}). However, according to their growth curve, a slower growth was observed for the AmB strain in medium containing 250 μM amphotericin B compared to the naive control in drug-free medium ([Fig. 1](#fig1){ref-type="fig"}). On the one hand, in the naive control strain, no lag phase was observed and the stationary phase was reached at the 5th day of culture, with a doubling time of around 22 h. On the other hand, the AmB strain displayed a lag phase of 2 days before starting the log phase and reaching the stationary phase at the 9th day of culture, with an extended doubling time of around 42 h. Nonetheless, the stationary phase was reached with a similar cell density in both cases at 2 × 10^6^ amoebae/mL to 2.5 × 10^6^ amoebae/mL. Interestingly, the AmB strain displayed a similar growth after each passage in the presence of the drug, without showing a tendancy to recover a growth curve related to the naive control strain. Furthermore, when the AmB strain was transferred to an amphotericin B-free medium, a growth curve similar to the naive control strain was observed, indicating the ability of these amoebae to recover the fitness of the control strain in only one passage in the absence of the drug ([Fig. 1](#fig1){ref-type="fig"}). Additionally, when a naive control strain was transferred to a medium containing 250 μM amphotericin B, amoebae proliferated slowly with a lag phase and a longer log phase, as for the AmB strain in the presence of the drug, from the first passage ([Fig. 1](#fig1){ref-type="fig"}). Altogether, these results show that, besides the incapacity to select an *A. castellanii* strain resistant to amphotericin B ([Table 5](#tbl5){ref-type="table"}), the adaptation of the AmB strain to the drug was reversible and, more importantly, not acquired, as opposed to an acquired phenomenon of resistance. As the amoebae returned to an initial state of susceptibility for amphotericin B at each new passage in a medium containing the drug, this phenomenon was qualified as "resilience". To our knowledge, this is the first time that such phenomenon was described for amphotericin B in *Acanthamoeba*.Fig. 1Effect of amphotericin B treatment on *Acanthamoeba castellanii* growth curve.Growth curves of naive *A. castellanii* cultured in the presence (◯) or absence (●) of 250 μM amphotericin B and of *A. castellanii* pre-incubated with 250 μM amphotericin B for 3 months cultured in the presence (□) or absence (■) of 250 μM amphotericin B. The curves were generated by counting amoebae under light microscope once (◯, ■) or twice (●, □) a day using a Malassez chamber. This analysis was performed using the *A. castellanii* ATCC 30010 strain. The results correspond to the mean of three independent experiments ± SD.Fig. 1Table 3Evolution of Amphotericin B IC~50~ at 3, 4 and 5 days of treatment on different strains of *A. castellanii* and *A. polyphaga*.Table 3StrainsIC~50~ (μM) ± SD at 3 daysIC~50~ (μM) ± SD at 4 daysIC~50~ (μM) ± SD at 5 days*A. castellanii* ATCC 300105.94 ± 0.8852.99 ± 9.27\>100*A. castellanii* CCAP 1534/35.43 ± 0.2545.10 ± 7.97\>100*A. polyphaga* ATCC 503712.13 ± 0.1945.90 ± 6.33\>100*A. polyphaga* CCAP 1501/3G7.15 ± 0.2574.74 ± 6.95\>100[^5]Table 4Effect of Amphotericin B pre-incubation in culture medium on IC~50~ evolution at 3, 4 and 5 days of treatment on *Acanthamoeba castellanii*.Table 4DrugsIC~50~ (μM) ± SD at 3 daysIC~50~ (μM) ± SD at 4 daysIC~50~ (μM) ± SD at 5 daysAmphotericin B control[a](#tbl4fna){ref-type="table-fn"}6.83 ± 0.5861.77 ± 13.81\>100Pre-incubated Amphotericin B[b](#tbl4fnb){ref-type="table-fn"}4.12 ± 0.1146.50 ± 9.62\>100[^6][^7][^8]Table 5Effect of *Acanthamoeba castellanii* pre-incubation with Amphotericin B on IC~50~ evolution at 3, 4 and 5 days after treatment.Table 5StrainsIC~50~ (μM) ± SD at 3 daysIC~50~ (μM) ± SD at 4 daysIC~50~ (μM) ± SD at 5 daysControl[a](#tbl5fna){ref-type="table-fn"}7.78 ± 0.8861.75 ± 5.35\>100AmB[b](#tbl5fnb){ref-type="table-fn"}5.78 ± 0.2470.21 ± 2.24\>100[^9][^10][^11]

Amphotericin B resilience was further investigated by treating amoebae with effectors altering specifically different cellular transports or pathways prior to evaluate antiacanthamoebal activity of amphotericin B at 3, 4 and 5 days of treatment. No change in IC~50~ evolution was observed when *A. castellanii* was treated with calcimycin, a calcium ionophore, or BAPTA-AM, an intracellular calcium chelator ([Fig. 2](#fig2){ref-type="fig"}A). The involvement of the cytoskeleton in amphotericin B resilience was also analyzed by inhibiting actin and tubulin polymerization with latrunculin B and vinblastine, respectively. These drugs were also ineffective to modify the amphotericin B IC~50~ increase from 3 to 5 days of treatment. Although no obvious increase in cyst proportion was observed when amoebae were cultured in the presence of amphotericin B (data not shown), the involvement of encystment was analyzed by treating *Acanthamoeba* with wortmannin and dichlorobenzonitrile (DCB), previously described to inhibit this cellular process in *A. castellanii* ([@bib11], [@bib31]). As shown in [Fig. 2](#fig2){ref-type="fig"}A, no effect on amphotericin B antiacanthamoebal activity was observed with these drugs. However, a treatment of the amoebae by KCN, valinomycin and glibenclamide, an inhibitor of oxygen consumption in the respiratory chain, a potassium ionophore and a potassium channel blocker, respectively, lead to a loss of IC~50~ increase at 4 and 5 days of treatment ([Fig. 2](#fig2){ref-type="fig"}A). A similar result was obtained with valspodar, an inhibitor of P-glycoprotein (PgP) involved in drug efflux and encoded by the multidrug resistance gene MDR-1 ([@bib3]). Interestingly, the increase of amphotericin B IC~50~ from 3 to 5 days of treatment was amplified with staurosporine, a pro-apoptotic kinase inhibitor, and, to a higher extent, with voriconazole which has been previously described to induce apoptosis in *A. castellanii* ([Fig. 2](#fig2){ref-type="fig"}B) ([@bib27]).Fig. 2Influence of effectors on the evolution of amphotericin B antiacanthamoebal activity.Amphotericin B antiacanthamoebal activity was evaluated at 3, 4 and 5 days of treatment in the presence of 100 μM potassium cyanide (KCN), 100 μM glibenclamide, 20 μM valinomycin, 1 μM calcimycin, 30 μM BAPTA-AM, 10 μM valspodar, 1 μM latrunculin B, 25 μM vinblastine, 50 μM wortmannin or 10 μM dichlorobenzonitrile (A), or 0.1 μM voriconazole or 1 μM staurosporine (B). These drug concentrations were determined to inhibit ≤25% of parasite growth after 3 days of incubation ([Table S1](#appsec1){ref-type="sec"}). Amoebae were pre-treated with drugs alone for 4 h at twice these concentrations prior to start the evaluation. The IC~50~ ratios correspond to the IC~50~ obtained at 3, 4 or 5 days normalized to the IC~50~ at 3 days. Thus, an increase in this ratio between 3 and 5 days of treatment reflects an increase of IC~50~. These evaluations were performed using the *Acanthamoeba castellanii* ATCC 30010 strain. The results correspond to the mean of three independent experiments ± SD.Fig. 2

An ultrastructural analysis was then performed on *A. castellanii* grown in the presence of 250 μM amphotericin B for 3, 7 and 10 days, corresponding to early- and late-log phase and stationary phase, respectively ([Fig. 1](#fig1){ref-type="fig"}). These amphotericin B-treated amoebae were compared to untreated control in log phase cultured for 3 days in drug-free medium ([Fig. 1](#fig1){ref-type="fig"}, [Fig. 3](#fig3){ref-type="fig"}A--D). Both amphotericin B-treated and untreated amoebae displayed multiple mitochondria in their cytoplasm ([Fig. 3](#fig3){ref-type="fig"}A,E,I,M). In contrast to the untreated control where the mitochondria exhibited inner and outer membranes delimitating evenly the matrix with well defined tubular cristae ([Fig. 3](#fig3){ref-type="fig"}B--D), the mitochondria of the amphotericin B-treated amoebae displayed some membrane bulges with poorly defined tubular cristae, especially after 3 and 7 days of culture ([Fig. 3](#fig3){ref-type="fig"}F--H and J--L). When the amphotericin B-treated amoebae reached the stationary phase, after 10 days of culture, tubular cristae were more discernible, but not well delineated as for the control ([Fig. 3](#fig3){ref-type="fig"}N,O). Double membranes surrounding either partially or entirely mitochondria were also observed in these non-dividing amoebae ([Fig. 3](#fig3){ref-type="fig"}N,O). Furthermore, intracristae granules were more frequently observed in mitochondria of amphotericin B-treated amoebae compared to the control ([Fig. 3](#fig3){ref-type="fig"}D,F,J,N,O).Fig. 3Ultrastructural analysis of *Acanthamoeba castellanii* treated with amphotericin B.*A. castellanii* cultured in absence of amphotericin B for a period of 3 days corresponding to the log phase (A-D), or in the presence of 250 μM amphotericin B for a period of 3 days (E-H), 7 days (I-L), or 10 days (M-O) corresponding to early-, late-log and stationary phase, respectively. Apart from the image K which is a higher magnification of image I, all images were collected from different cells at the following magnification: 1000× (A), 1200× (E), 1500× (I and M), 4000× (F), 5000× (B, C, J and N), 6000× (G and K), 8000× (H) and 10000× (D, L and O). These evaluations were performed using the *Acanthamoeba castellanii* ATCC 30010 strain. ★: mitochondria; N: Nucleus; WEV: Water-Expulsion Vesicle; g: intracristae granule; arrow: mitochondrial membrane swelling; arrowhead: double membrane surrounding mitochondria.Fig. 3

4. Discussion {#sec4}
=============

As the treatment of FLA remains empirical and the *in vitro* activities of antiacanthamoebal drugs reported in the literature are variable depending on the time of treatment or the *Acanthamoeba* species used ([@bib12], [@bib13], [@bib35], [@bib26], [@bib5], [@bib33], [@bib37]), the main objective of this study was to determine in our conditions the *in vitro* efficiency of clinically used antimicrobial agents on *A. castellanii* at different times of treatment in order to propose a rationale for their use in therapy. This approach was completed by a study deciphering the mechanism of action of amphotericin B showing a surprising evolution of antiacanthamoebal activity as a function of time.

Among the drugs evaluated for their *in vitro* anti-*Acanthamoeba* activity, the best activity was obtained with hexamidine, a diamidine containing an alkyl chain of 6 carbons, with a stable IC~50~ at 0.05 μM at 3, 4 and 5 days of treatment. Hexamidine is used as a first-line treatment for AK in combination with chlorhexidine, which also showed in our study an interesting IC~50~ in the micromolar range ([@bib46], [@bib5]). Two other diamidines presenting shorter alkyl chain of 3 and 5 carbons, namely propamidine and pentamidine, respectively, were evaluated in this work. Propamidine is commonly used in the treatment of AK, while pentamidine has been occasionally employed in GAE therapy ([@bib44], [@bib46], [@bib5], [@bib36]). Higher IC~50~ values at around 10 μM and 1 μM, at either 3, 4 or 5 days of treatment, were obtained with propamidine and pentamidine compared to hexamidine, indicating an increase of anti-*Acanthamoeba* activity in relation with the length of diamidine alkyl chain. These results are in agreement with a previous study showing that the antiacanthamoebal activity of diamidines is proportional to the length of their alkyl chain ([@bib38]). The three azoles evaluated in this work, namely voriconazole, clotrimazole and ketoconazole, have been previously used for the treatment of *Acanthamoeba* infections ([@bib44], [@bib36]). Among these azoles, voriconazole and clotrimazole showed the best antiacanthamoebal activities with IC~50~ values in the submicromolar range while ketoconazole IC~50~ values were at around 10 μM, independently of the treatment duration. These results are in agreement with a previous work showing that clotrimazole has the best *in vitro* antiacanthamoebal activity in comparison with other azoles such as bifonazole, ketoconazole, itraconazole and fluconazole ([@bib43]). Flucytosine and miltefosine are two other compounds that have been used in *Acanthamoeba* infections ([@bib44], [@bib46], [@bib36]) exhibiting interesting IC~50~ values between 4.5 μM and 8 μM and at around 10 μM, respectively. No significant variation of IC~50~ was observed with these drugs as a function of time. While some *Acanthamoeba* strains have been described to be capable of growing at flucytosine concentrations as high as 310 μM ([@bib50]), the antiacanthamoebal activity of miltefosine reported in the literature is in agreement with the IC~50~ values obtained in the present study ([@bib30]). The difference observed with flucytosine between the study of [@bib50] and our work may be due to the use of distinct *Acanthamoeba* strains. Despite that paromomycin has been rarely used in the treatment of *Acanthamoeba* infections with unconvincing outcomes ([@bib47]), this drug displayed a modest *in vitro* antiacanthamoebal activity in our conditions with IC~50~ values between 16 μM and 20 μM at either 3, 4 or 5 days of treatment, which is in agreement with the IC~50~ values previously obtained with the same *A. castellanii* strain as well as with several *Acanthamoeba* isolates ([@bib33]). Furthermore, metronidazole, which has been also infrequently used in the treatment of AK or GAE ([@bib20], [@bib17]), was inactive on *A. castellanii* in our study, although an IC~50~ value at 17.5 μM was obtained with this drug on another *Acanthamoeba* species, *A. polyphaga* ([@bib35]). Surprisingly, in line with a previous work showing an absence of *in vitro* activity of rifampicin on *A. polyphaga* ([@bib35]), rifampicin as well as cotrimoxazole, two drugs that are frequently used in GAE treatment ([@bib44], [@bib46], [@bib36]), did not display an *in vitro* antiacanthamoebal activity in our conditions (IC~50~ \> 100 μM) revealing a possible inappropriate utilization of these drugs in *Acanthamoeba* infections. Among the drug combinations analyzed in this work, no one displayed a synergistic effect, except for the association of hexamidine and chlorhexidine which exhibited an antagonistic effect. These results indicate that a particular care should be exercised when hexamidine and chlorhexidine are associated in the treatment of *Acanthamoeba* infections, especially as the first-line therapy for AK involves the combination of membrane-acting agents, such as polyhexamethylene biguanide or chlorhexidine, with a diamidine (propamidine, pentamidine or hexamidine; [@bib46], [@bib5]).

In our study, all drugs showed a stable IC~50~ as a function of time, except for amphotericin B which displayed an intriguing decrease of activity between 3 and 5 days of treatment. This drug, which has been frequently used for the treatment of GAE ([@bib44], [@bib46], [@bib5]), exhibited an IC~50~ value at 6.78 μM at 3 days of treatment. This result was in agreement with IC~50~ values previously reported at the same time of treatment on *A. polyphaga* ([@bib35]). Another study showed higher IC~50~ values of amphotericin B, between 25 μM and 67 μM, on *Acanthamoba* sp. isolates after a treatment of 4 days, in line with our results ([@bib26]). The decrease of antiacanthamoebal activity of amphotericin B as a function of time was also observed in a previous study where the MIC~100~ (minimal concentration inhibiting 100% of amoebae growth) of amphotericin B was determined at 6.76 μM, 108 μM and above 108 μM at 2, 3 and 6 days of treatment, respectively ([@bib29]). However, these authors did not investigate this phenomenon further and observed this change of activity with other antimicrobial agents as well, such as acyclovir or polymyxin B. In our study, amphotericin B was the only drug displaying a change of antiacanthamoebal activity as a function of time. This phenomenon was not altered by incubating amphotericin B in culture medium prior to *in vitro* antiacanthamoebal evaluation and was observed with several strains of two different species of *Acanthamoeba* (*A. castellanii* and *A. polyphaga*), showing that the increase of amphotericin B IC~50~ as a function of time was not due to drug degradation in the medium and could be potentially generalized to the genus *Acanthamoeba*. Furthermore, no resistant strain could have been selected as the susceptibility of *Acanthamoeba castellanii* for amphotericin B at 3, 4 and 5 days of treatment was similar between naive control amoebae and *A. castellanii* cultured for 3 months in the presence of 250 μM amphotericin B. This phenomenon of adaptation to amphotericin B was thus qualified as resilience as the amoebae did not acquire a resistance phenotype, but rather returned to an initial state of susceptibility at each passage in the presence of the drug. Nonetheless, microbial communities under a pressing disturbance, in opposition to a pulse disturbance, have the tendancy to create a stable state of resistance rather than returning to an initial state of susceptibility and to develop resilience ([@bib45]). Therefore, in our case, *Acanthamoeba* has surprisingly adopted a strategy of resilience rather than resistance against amphotericin B probably due to a more advantageous fitness cost.

An approach to understand the mechanism of action of amphotericin B was to use pharmacological tools having specific actions on a cell. The treatment of amoebae with a calcium ionophore (calcimycin), an intracellular calcium chelator (BAPTA-AM), or inhibitors of encystment (wortmannin and DCB), or actin and tubulin polymerization (latrunculin B and vinblastine, respectively), did not alter amphotericin B IC~50~ evolution with time. Although calcimycin and BAPTA-AM displayed an IC~50~ at 1.97 μM and 73.08 μM on *A. castellanii* after 3 days of treatment, respectively ([Table S1](#appsec1){ref-type="sec"}), to our knowledge, the mode of action of these drugs on calcium channels or intracellular calcium in *Acanthamoeba* has not been investigated. Furthermore, the lack of action of vinblastine is consistent with a previous work showing that *Acanthamoeba* tubulin was resistant to this drug ([@bib19]). Therefore, an absence of activity of calcimycin, BAPTA-AM or vinblastine on the increase of amphotericin B IC~50~ between 3 and 5 days of treatment does not exclude the involvement of calcium or tubulin in the phenomenon of amphotericin B resilience. In relation with the inefficiency of encystment inhibitors to impact the amphotericin B IC~50~ increase with time, no obvious expansion of cyst proportion was observed when amoebae were cultured in the presence of the drug. Furthermore, the action of wortmannin and DCB on the inhibition of encystment, and of latrunculin B on actin depolymerization have been previously described in *A. castellanii* ([@bib11], [@bib49], [@bib31]), suggesting that encystment and actin polymerization are not involved in amphotericin B resilience.

Although potassium cyanide has been reported to generate a collapse of the mitochondrial membrane potential ([@bib21]), it did not present an antiacanthamoebal activity in our conditions ([Table S1](#appsec1){ref-type="sec"}). This lack of activity may be due to the existence of two branching pathways in the respiratory chain of *A. castellanii*, one classical cytochrome pathway and one cyanide-resistant non-electrogenic alternative oxidase pathway ([@bib21]). In agreement with a previous study showing that valinomycin has only a limited and transient effect on membrane potential of *Acanthamoeba castellanii* ([@bib10]), a negligeable antiacanthamoebal activity was obtained with this drug in our work ([Table S1](#appsec1){ref-type="sec"}). Likewise, glibenclamide was inefficient on *A. castellanii* with an IC~50~ above 100 μM at 3 days of treatment. Nonetheless, glibenclamide and valinomycin have been described to act on the membrane potential of mitochondria isolated from *A. castellanii* ([@bib23]). In the present study, KCN, glibenclamide, and valinomycin inhibited amphotericin B IC~50~ increase as a function of time, indicating that mitochondrial membrane potential is required in the phenomenon of amphotericin B resilience in *Acanthamoeba*. Furthermore, in mammalian cells, glibenclamide and valinomycin have been reported to block the multidrug resistance proteins MRP-1 and PgP, respectively, involved in drug efflux ([@bib55], [@bib8]). Valspodar, another PgP inhibitor ([@bib3]), also prevented amphotericin B IC~50~ increase with time, showing that besides mitochondrial membrane potential, multidrug resistance transporters are also involved in amphotericin B resilience in *Acanthamoeba*. Consistently, amphotericin B resistance in the protozoan parasite *Leishmania* has been noticeably characterized by an increase of MDR-1 expression level, encoding for PgP ([@bib40]). A low level of ergosterol has also been associated with amphotericin B resistance in this kinetoplastid parasite as well as in fungi ([@bib40], [@bib9]). Moreover, a disruption of mitochondrial function in *Candida albicans* has been described to result in a reduction of cellular ergosterol levels and an increase of amphotericin B resistance ([@bib15]). Therefore, the mechanism of amphotericin B resistance in *Leishmania* and in fungi involves several factors, such as mitochondrial function or multidrug resistance transporters, that are also used in the phenomenon of amphotericin B resilience in *Acanthamoeba.* Nonetheless, in the latter case, these factors would not be acquired from one passage to another.

The amplification of amphotericin B IC~50~ increase with time by using pro-apoptotic compounds, such as staurosporine and voriconazole ([@bib27]), indicate that an apoptosis-like pathway is involved in the phenomenon of amphotericin B resilience in *Acanthamoeba*. Programmed cell death has also been implicated in the mode of action of amphotericin B in fungi and in *Leishmania* ([@bib25], [@bib32], [@bib7]). In particular, amphotericin B treatment in *C. albicans* has been shown to activate mitochondrial activity leading to an excess of ROS and subsequently cell death ([@bib2]). Two main apoptotic pathways are currently described in eukaryotic cells: the extrinsic or death receptor pathway, and the intrinsic or mitochondrial pathway ([@bib14]). In this latter pathway, mitochondria are required as both a source and a target of oxidative stress, which is principally triggered by an overproduction of ROS, leading to a loss of mitochondrial membrane potential, and ultimately cell death. Nonetheless, *A. castellanii* mitochondria have been described to resist for a period of 5 min to oxidative stress induced by H~2~O~2~ at up to 25 mM ([@bib22]). Based on our results, our hypothesis would be that an apoptosis-like pathway, requiring a functional mitochondrial membrane potential for initial activation, would be induced during amphotericin B resilience in *Acanthamoeba*. This pathway would be then redirected to allow amoebae survival and proliferation in the presence of amphotericin B. In agreement with our results, a previous work performed in *C. albicans* isolates has shown that despite an induction of early apoptosis markers following amphotericin B treatment, some cells were able to recover and to form colonies on plates, indicating the possibility to redirect the programmed cell death pathway induced in amphotericin B treated cells ([@bib56]). Reversibility of apoptotic pathways has also been observed in other eukaryotic organisms ([@bib14]).

Ultrastructural analysis of amphotericin B treated *Acanthamoeba* revealed a strong alteration of mitochondrial cristae after 3 and 7 days of treatment. Similar events of mitochondrial cristae alteration have been depicted in acanthamoebal cysts characterized by a lower respiration rate ([@bib4]). The shape of mitochondrial cristae has also been shown to be altered during apoptosis and to modulate the respiratory efficiency in mammalian cells ([@bib6]). Our study indicate that apoptosis, as opposed to encystment, is involved in the phenomenon of amphotericin B resilience. Therefore, alteration of mitochondrial cristae would be induced in the apoptosis-like pathway activated following amphotericin B treatment, as well as in encystment, but it would not be sufficient for the achievement of this latter process. At 10 days of treatment, mitochondrial cristae were less altered but some double membranes, similar to autophagosomes, were observed surrounding mitochondria either totally or partially. This process of mitophagy, defined as a quality control mechanism eliminating damaged mitochondria, was only noticed in stationary phase amoebae and could be a consequence of mitochondrial alterations observed in the log phase. In agreement with these results, mitochondrial lesions can induce mitophagy in yeast ([@bib39]). Moreover, a high degree of crosstalk has been identified between mitophagy and apoptosis ([@bib18]), showing that the phenomenon of amphotericin B resilience is a complex mechanism involving several mitochondria-dependent pathways.

5. Conclusion {#sec5}
=============

Among the 15 antimicrobial agents analyzed in this work, hexamidine, voriconazole, and clotrimazole exhibited the best *in vitro* antiacanthamoebal activities. No synergistic effect was observed with any of the drug associations evaluated, and an antagonism was determined for hexamidine-chlorhexidine. Interestingly, the adaptation of *Acanthamoeba* to amphotericin B always returned to an initial level of susceptibility, reflecting the establishment of a non-acquired phenomenon, qualified as resilience. The analysis of its mechanism revealed the involvement of mitochondria-dependent pathways and multidrug resistance transporters. Further works, including proteomics or metabolomics approaches, would allow to decipher these pathways in details and to identify the molecular mediators induced during the phenomenon of amphotericin B resilience in *Acanthamoeba*.

Appendix A. Supplementary data {#appsec1}
==============================

The following is the supplementary data related to this article:Table S1Table S1
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[^1]: ^∗^These drugs have not, or rarely, been used in the treatment of *Acanthamoeba* infections. The *A. castellanii* ATCC 30010 strain was used in these evaluations. The results correspond to the mean of six independent experiments ±SD. ND = Not determined.

[^2]: Amphotericin B appears in bold.

[^3]: These evaluations were performed on the *A. castellanii* ATCC 30010 strain. FICI were calculated from the anti-*Acanthamoeba* activities of drug combinations after 3 days of treatment. FICI ≤0.5 = synergistic effect; 0.5 \< FICI ≤4 = additive effect; FICI \>4 = antagonistic effect. Results correspond to the mean of four independent experiments ± SD.

[^4]: FICI = Fractional Inhibitory Concentration Index.

[^5]: The results correspond to the mean of three independent experiments ± SD.

[^6]: These evaluations were performed on the *A. castellanii* ATCC 30010 strain. The results correspond to the mean of three independent experiments ± SD.

[^7]: Amphotericin B was directly used after dilution in culture medium for *A. castellanii* treatment.

[^8]: Amphotericin B was incubated for 7 days at 27 °C in culture medium before *A. castellanii* treatment.

[^9]: These evaluations were performed on the *A. castellanii* ATCC 30010 strain. The results correspond to the mean of three independent experiments ± SD.

[^10]: Control = Naive *A. castellanii* cultured in absence of amphotericin B.

[^11]: AmB = *A. castellanii* pre-incubated with 250 μM amphotericin B in culture medium for 3 months before evaluation of amphotericin B activity.
